What question did this study set out to answer?

To review preclinical, imaging, and clinical evidence characterizing the direct and indirect prothrombotic mechanisms through which lipoprotein(a) contributes to atherothrombotic cardiovascular risk.

August 5, 2026Current Opinion in Lipidology

Lipoprotein(a): a unique lipoprotein at the crossroads of atherosclerosis and thrombosis

View Full Paper

Ask AI

Bookmark

Authors

MBMichael B. BoffaWestern University MKMarlys L. KoschinskyWestern University

Discussion

Member takes

Overview

Narrative review reveals dual proatherogenic and prothrombotic mechanisms of lipoprotein(a) in cardiovascular disease, indicating potential targets for personalized prevention and therapy.

Key Points

To review preclinical, imaging, and clinical evidence characterizing the direct and indirect prothrombotic mechanisms through which lipoprotein(a) contributes to atherothrombotic cardiovascular risk.
Literature synthesis of preclinical mechanistic studies, clinical plaque imaging investigations, and primary prevention trials evaluating lipoprotein(a) pathophysiology and therapy.
Preclinical models and vascular imaging demonstrate that oxidized phospholipids carried by lipoprotein(a) incite vascular inflammation and drive vulnerable plaque formation.
Lipoprotein(a) directly promotes thrombosis by inducing lysis-resistant fibrin clot architectures, activating the coagulation cascade, and enhancing platelet reactivity.
Primary prevention analyses demonstrate selective clinical risk reduction from aspirin therapy in individuals presenting with elevated baseline lipoprotein(a) concentrations.

Cite This Study

Boffa et al. (2026) studied this question.

synapsesocial.com/papers/6a9f674eaccb0daecaf7deec https://doi.org/10.1097/mol.0000000000001049

View Full Paper

Ask AI

Bookmark

August 5, 2026Current Opinion in Lipidology

Lipoprotein(a): a unique lipoprotein at the crossroads of atherosclerosis and thrombosis

View Full Paper

Ask AI

Bookmark

Authors

MBMichael B. BoffaWestern University MKMarlys L. KoschinskyWestern University

Discussion

Member takes

Overview

Narrative review reveals dual proatherogenic and prothrombotic mechanisms of lipoprotein(a) in cardiovascular disease, indicating potential targets for personalized prevention and therapy.

Key Points

To review preclinical, imaging, and clinical evidence characterizing the direct and indirect prothrombotic mechanisms through which lipoprotein(a) contributes to atherothrombotic cardiovascular risk.
Literature synthesis of preclinical mechanistic studies, clinical plaque imaging investigations, and primary prevention trials evaluating lipoprotein(a) pathophysiology and therapy.
Preclinical models and vascular imaging demonstrate that oxidized phospholipids carried by lipoprotein(a) incite vascular inflammation and drive vulnerable plaque formation.
Lipoprotein(a) directly promotes thrombosis by inducing lysis-resistant fibrin clot architectures, activating the coagulation cascade, and enhancing platelet reactivity.
Primary prevention analyses demonstrate selective clinical risk reduction from aspirin therapy in individuals presenting with elevated baseline lipoprotein(a) concentrations.

Cite This Study

Boffa et al. (2026) studied this question.

synapsesocial.com/papers/6a9f674eaccb0daecaf7deec https://doi.org/10.1097/mol.0000000000001049

View Full Paper

Ask AI

Bookmark